US 12,168,778 B2
Cardiac cell reprogramming with myocardin and ASCL1
Huanyu Zhou, San Mateo, CA (US); and Laura Lombardi, Redwood City, CA (US)
Assigned to Tenaya Therapeutics, Inc., South San Francisco, CA (US)
Filed by Tenaya Therapeutics, Inc., South San Francisco, CA (US)
Filed on Sep. 15, 2023, as Appl. No. 18/468,652.
Application 18/468,652 is a continuation of application No. 17/211,559, filed on Mar. 24, 2021.
Application 17/211,559 is a continuation of application No. 17/028,881, filed on Sep. 22, 2020, granted, now 11,015,211, issued on May 25, 2021.
Application 17/028,881 is a continuation of application No. PCT/US2019/049150, filed on Aug. 30, 2019.
Claims priority of provisional application 62/725,168, filed on Aug. 30, 2018.
Claims priority of provisional application 62/852,746, filed on May 24, 2019.
Claims priority of provisional application 62/788,479, filed on Jan. 4, 2019.
Prior Publication US 2024/0052369 A1, Feb. 15, 2024
Int. Cl. C12N 15/86 (2006.01); A61K 38/17 (2006.01); A61K 48/00 (2006.01); C12N 7/00 (2006.01)
CPC C12N 15/86 (2013.01) [A61K 38/1719 (2013.01); A61K 48/005 (2013.01); C12N 7/00 (2013.01); C12N 2750/14143 (2013.01); C12N 2750/14171 (2013.01)] 14 Claims
 
1. An engineered human myocardin (MYOCD) polynucleotide encoding an engineered myocardin protein, wherein
the engineered myocardin protein comprises a deletion of at least 200 amino acids in the region corresponding to amino acids 414-764 of a human myocardin protein of SEQ ID NO: 3.